Literature DB >> 23180998

Economic and microbiologic evaluation of single-dose vial extension for hazardous drugs.

Erinn C Rowe1, Scott W Savage, William A Rutala, David J Weber, Maria Gergen-Teague, Stephen F Eckel.   

Abstract

PURPOSE: The update of US Pharmacopeia Chapter <797> in 2008 included guidelines stating that single-dose vials (SDVs) opened and maintained in an International Organization for Standardization Class 5 environment can be used for up to 6 hours after initial puncture. A study was conducted to evaluate the cost of discarding vials after 6 hours and to further test sterility of vials beyond this time point, subsequently defined as the beyond-use date (BUD).
METHODS: Financial determination of SDV waste included 2 months of retrospective review of all doses prescribed. Additionally, actual waste log data were collected. Active and control vials (prepared using sterilized trypticase soy broth) were recovered, instead of discarded, at the defined 6-hour BUD.
RESULTS: The institution-specific waste of 19 selected SDV medications discarded at 6 hours was calculated at $766,000 annually, and tracking waste logs for these same medications was recorded at $770,000 annually. Microbiologic testing of vial extension beyond 6 hours showed that 11 (1.86%) of 592 samples had one colony-forming unit on one of two plates. Positive plates were negative at subsequent time points, and all positives were single isolates most likely introduced during the plating process.
CONCLUSION: The cost of discarding vials at 6 hours was significant for hazardous medications in a large academic medical center. On the basis of microbiologic data, vial BUD extension demonstrated a contamination frequency of 1.86%, which likely represented exogenous contamination; vial BUD extension for the tested drugs showed no growth at subsequent time points and could provide an annual cost savings of more than $600,000.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23180998      PMCID: PMC3396829          DOI: 10.1200/JOP.2011.000488

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  7 in total

1.  Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States.

Authors:  T H Connor; R W Anderson; P J Sessink; L Broadfield; L A Power
Journal:  Am J Health Syst Pharm       Date:  1999-07-15       Impact factor: 2.637

2.  Using a closed-system protective device to reduce personnel exposure to antineoplastic agents.

Authors:  Catherine Wick; Matthew H Slawson; James A Jorgenson; Linda S Tyler
Journal:  Am J Health Syst Pharm       Date:  2003-11-15       Impact factor: 2.637

3.  A prescription for drug shortages.

Authors:  Barbara K Gehrett
Journal:  JAMA       Date:  2012-01-11       Impact factor: 56.272

4.  Impact of United States Pharmacopeia chapter 797: results of a national survey.

Authors:  Timothy A Candy; Philip J Schneider; Craig A Pedersen
Journal:  Am J Health Syst Pharm       Date:  2006-07-15       Impact factor: 2.637

5.  Microbiological challenge of four protective devices for the reconstitution of cytotoxic agents.

Authors:  K De Prijck; E D'Haese; J Vandenbroucke; W Coucke; H Robays; H J Nelis
Journal:  Lett Appl Microbiol       Date:  2008-12       Impact factor: 2.858

6.  Barrier properties and cost implications of a single versus a double wrap for storing sterile instrument packs.

Authors:  Joan Webster; Elinor Radke; Narelle George; Joan Faoagali; Mary Harris
Journal:  Am J Infect Control       Date:  2005-08       Impact factor: 2.918

7.  Effect of two work practice changes on the microbial contamination rates of pharmacy-compounded sterile preparations.

Authors:  Lawrence A Trissel; Joseph A Gentempo; Lisa M Saenz; Monica Y Woodard; Carol H Angeles
Journal:  Am J Health Syst Pharm       Date:  2007-04-15       Impact factor: 2.637

  7 in total
  5 in total

1.  Review of economic data on closed system transfer drug for preparation and administration of hazardous drugs.

Authors:  Annaelle Soubieux; Cynthia Tanguay; Jean Lachaine; Jean-François Bussières
Journal:  Eur J Hosp Pharm       Date:  2019-02-22

2. 

Authors:  Annaelle Soubieux; Caroline Plante; Johann-François Ouellette-Frève; Audrey Chouinard; Jean-François Bussières
Journal:  Can J Hosp Pharm       Date:  2020-02-01

Review 3.  Review of studies examining microbial contamination of vials used for preparations done with closed-system drug transfer devices.

Authors:  Annaelle Soubieux; Cynthia Tanguay; Jean-François Bussières
Journal:  Eur J Hosp Pharm       Date:  2019-05-15

4.  Cost Analysis of Using a Closed-System Transfer Device (CSTD) for Antineoplastic Drug preparation in a Malaysian Government-Funded Hospital

Authors:  Huan Keat Chan; Yik Ming Lim
Journal:  Asian Pac J Cancer Prev       Date:  2016-11-01

5.  Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners.

Authors:  Manmeet Khaira; Allison L Guy
Journal:  J Oncol Pharm Pract       Date:  2021-05-18       Impact factor: 1.416

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.